O Brien Greene & Co. Inc Trims Holdings in Johnson & Johnson $JNJ

O Brien Greene & Co. Inc lowered its position in Johnson & Johnson (NYSE:JNJ) by 5.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,458 shares of the company’s stock after selling 400 shares during the period. O Brien Greene & Co. Inc’s holdings in Johnson & Johnson were worth $986,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $35,000. Stone House Investment Management LLC purchased a new position in Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Pandora Wealth Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $65,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. The Goldman Sachs Group upped their price target on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. HSBC lifted their price target on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Finally, Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Price Performance

Shares of JNJ opened at $186.92 on Friday. The firm has a 50-day simple moving average of $184.06 and a two-hundred day simple moving average of $168.42. The stock has a market cap of $450.33 billion, a PE ratio of 18.04, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.